Why your anesthesia team cares about your GLP-1
Semaglutide and tirzepatide slow how quickly the stomach empties. That is part of how they curb appetite, but it means food can still be sitting in the stomach hours after the usual fasting window. Under general anesthesia or deep sedation, the reflexes that protect your airway are switched off, so stomach contents can travel up and into the lungs. That is called aspiration, and it can cause a serious pneumonia.
The Wegovy label describes rare postmarketing reports of aspiration in people on GLP-1 medicines who had food left in their stomach despite following fasting instructions. It also says the available data are not enough to show whether changing fasting rules or pausing the medicine reduces that risk. That gap is why the advice has shifted.
Two more details shape the current thinking. The ASA’s 2023 document notes that the stomach-slowing effect is reported to fade with long-term use, which helps explain why risk is highest early in treatment. And these medicines are now common: the ASA’s 2024 announcement estimates that about one in eight U.S. adults use a GLP-1 drug, so a blanket rule touches a very large number of procedures.
The 2023 advice: hold the dose before elective procedures
In June 2023, the American Society of Anesthesiologists (ASA) issued consensus guidance based on a small number of case reports. For elective procedures, it suggested:
- holding daily GLP-1 medicines on the day of the procedure;
- holding weekly GLP-1 medicines for a week before the procedure, regardless of dose or the reason for taking them;
- considering a delay if severe nausea, vomiting, bloating or belly pain was present that day;
- using full-stomach precautions, or a bedside gastric ultrasound where available, if the medicine had not been held.
That approach was simple to follow, and many surgical centers adopted it. Its drawbacks showed up quickly. A skipped week could push blood sugar up in people with diabetes, and it applied the same rule to people with very different levels of risk.
The 2024 multisociety guidance: most people can continue
On October 29, 2024, the ASA joined the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity and the Society of American Gastrointestinal and Endoscopic Surgeons in new guidance. Its headline: most patients should continue their GLP-1 before elective surgery.
Instead of holding the drug for everyone, the guidance focuses on who is at higher risk of a full stomach:
- people in the dose-escalation phase, which typically lasts four to eight weeks, for whom elective surgery should wait until escalation and stomach symptoms have passed;
- people with nausea, vomiting, belly pain or constipation, who should wait until symptoms settle;
- people on higher doses, who should follow a liquid-only diet for 24 hours before the procedure;
- people with other conditions that slow the stomach, such as Parkinson’s disease.
The team can also adjust the anesthesia plan and use point-of-care ultrasound just before the procedure to check the stomach. The guidance notes that stopping the medicine has its own costs, including higher blood sugar in people with diabetes, and that holding it only because of a patient’s weight could amount to bias.
| ASA 2023 | Multisociety 2024 | |
|---|---|---|
| Default for weekly GLP-1 | Hold for one week | Usually continue |
| Main tool for higher-risk patients | Holding the dose | 24-hour liquid diet, timing, ultrasound |
| Stomach symptoms on the day | Consider delay | Wait until symptoms resolve |
| Who decides | Anesthesia team | Shared decision with anesthesia, surgeon and the GLP-1 care team |
Endoscopy, colonoscopy and dental sedation
The guidance covers any elective procedure with general anesthesia or deep sedation, not only operations. That includes many colonoscopies and upper endoscopies, and some dental and cosmetic procedures done under sedation. Because the gastroenterology and endoscopic surgery societies co-wrote it, endoscopy units generally follow the same logic.
Do not assume a short procedure is exempt. If sedation is planned, the stomach question applies.
What to tell your surgeon or endoscopist
Raise it at the scheduling call, not the morning of the procedure. Have these details ready:
- the medicine and dose, for example semaglutide 1.7 mg weekly or tirzepatide 10 mg weekly;
- your injection day and the date of your last dose increase;
- any nausea, vomiting, bloating, reflux or constipation in the past week;
- whether you have diabetes and what other diabetes medicines you take;
- who manages your GLP-1, so the teams can talk.
Then ask three questions: Should I take my usual dose? Do you want me on a liquid diet the day before? Would it be safer to schedule after my dose has been stable for a while? Do not stop or skip doses on your own; follow the plan your surgical team and the clinician managing your medicine agree on. Our quick answer on stopping semaglutide before surgery is a handy summary, and if you are also on testosterone therapy, see stopping TRT before surgery.
Restarting after a planned pause
If your team does ask you to hold a dose, ask before restarting rather than simply picking up where you left off. The Wegovy label advises that if two or more consecutive weekly doses are missed, the dose should be stepped back up from a lower level to reduce stomach side effects. One skipped week does not meet that threshold, but recovery from surgery and some pain medicines bring their own nausea, so the restart timing is worth a short conversation.
How Ultimate Male coordinates with your surgical team
If you are a medical weight loss patient with us, tell us as soon as a procedure is booked. Your provider can document your current dose, injection day and recent side effects, time any planned dose increase so you are not mid-escalation on surgery day, and talk with your surgeon or anesthesia team if they want input.
The final call on holding or continuing belongs to the team doing the procedure. If something goes wrong in the meantime, such as vomiting you cannot control or severe belly pain, our GLP-1 warning signs guide explains when to call the clinic and when to go to the ER, and our missed semaglutide dose answer covers how to restart safely after a planned pause.
